Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CASP1 | P29466 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | STAT3 | P40763 | 2/20 | 0.64 |
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13666112 | 0.99 | MAPT (0.73) | MAPTLMNASMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL13666102 | 0.95 | MAPT (0.68) | MAPTLMNASMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL5055275 | 0.88 | MAPT (0.67) | MAPTLMNASMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL5055199 | 0.81 | FAAH (0.64) | MAPTLMNASMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL5060772 | 0.77 | FAAH (0.76) | MAPTMAPK1RAB9A | |
| SCHEMBL13666099 | 0.76 | HCAR2 (1.00) | SMN1; SMN2ALDH1A1HCAR2KMT2ANPC1 | |
| SCHEMBL5056822 | 0.76 | HCAR2 (0.72) | HCAR2KMT2A | |
| SCHEMBL5275554 | 0.76 | FAAH (0.77) | MAPTMAPK1RAB9A | |
| SCHEMBL5055256 | 0.76 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL18711482 | 0.75 | NPC1 (0.74) | MAPTLMNASMN1; SMN2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | SMITHKLINE BEECHAM CORPORATION | 2008-06-12 | — | — | US | claimed |
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | SMITHKLINE BEECHAM CORPORATION | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | ANTXR2, CYP46A1, HCAR1 | MAPT 4881/4885LMNA 1163/4885SMN1; SMN2 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.